Cardiovascular Risk Assessment Using Genetic Polymorphisms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for calculating cardiovascular risk are inadequate, particularly for individuals with intermediate risk and young people, as they often fail to provide accurate predictions, leading to missed opportunities for preventive measures.
Innovation Solution
A method involving the determination of specific polymorphisms at positions 27 within nucleic acid sequences, which, when present, indicate a higher risk of cardiovascular events, allowing for more precise risk stratification and improved predictive models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional risk factor-based methods are used for cardiovascular risk calculation, then the assessment is simple and widely applicable, but the prediction accuracy is insufficient particularly for intermediate-risk individuals and young people
Solution Approach 1:
The patent applies parameter changes by incorporating genetic polymorphism data (specific SNPs at positions 27 within nucleic acid sequences) as additional parameters to the traditional cardiovascular risk assessment model. This enhances the prediction accuracy by adding biological variability parameters that differentiate individuals with similar traditional risk factors, particularly improving stratification for intermediate-risk groups and young individuals.
Solution Approach 2:
The patent creates a composite risk assessment model that integrates multiple types of data: traditional cardiovascular risk factors (age, blood pressure, cholesterol, smoking status) combined with genetic polymorphism information. This composite approach allows the system to leverage both the simplicity of traditional metrics and the precision of genetic markers, achieving improved accuracy without completely replacing the established assessment framework.
2Reliability
If genetic polymorphism analysis is added to improve risk stratification precision, then the identification of high-risk individuals improves, but the cost and complexity of the assessment increases
Solution Approach 1:
The patent segments the risk assessment process into distinct components: traditional risk factor evaluation and genetic polymorphism analysis. This segmentation allows the genetic testing to be performed as a separate, optional module that can be added to existing assessment protocols, making implementation more manageable and allowing gradual adoption without requiring complete system replacement.
Solution Approach 2:
The patent uses genetic polymorphism data as an intermediary marker that bridges traditional risk factors and actual cardiovascular events. These genetic markers serve as mediators that provide additional information about individual susceptibility, allowing clinicians to refine risk stratification without directly measuring complex biological pathways or conducting elaborate diagnostic procedures.
Data Source
AI summary
The invention relates to a method for the reclassification of a subject to a more appropriate risk assessment to that obtained using the algorithms for such risk estimation such us but not limited to Framingham, Regicor, Score, Procamor Qrisk based on the presence of different polymorphisms. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method.